Titre : Séquence riche en AT

Séquence riche en AT : Questions médicales fréquentes

Termes MeSH sélectionnés :

Computer Graphics
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Séquence riche en AT : Questions médicales les plus fréquentes", "headline": "Séquence riche en AT : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Séquence riche en AT : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-12", "dateModified": "2025-02-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Séquence riche en AT" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Structures génétiques", "url": "https://questionsmedicales.fr/mesh/D040342", "about": { "@type": "MedicalCondition", "name": "Structures génétiques", "code": { "@type": "MedicalCode", "code": "D040342", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360" } } }, "about": { "@type": "MedicalCondition", "name": "Séquence riche en AT", "alternateName": "AT Rich Sequence", "code": { "@type": "MedicalCode", "code": "D020856", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Norio Matsushima", "url": "https://questionsmedicales.fr/author/Norio%20Matsushima", "affiliation": { "@type": "Organization", "name": "Center for Medical Education, Sapporo Medical University, Sapporo 060-8556, Japan." } }, { "@type": "Person", "name": "Robert H Kretsinger", "url": "https://questionsmedicales.fr/author/Robert%20H%20Kretsinger", "affiliation": { "@type": "Organization", "name": "Department of Biology, University of Virginia, Charlottesville, VA 22904, United States." } }, { "@type": "Person", "name": "Hiroki Miyashita", "url": "https://questionsmedicales.fr/author/Hiroki%20Miyashita", "affiliation": { "@type": "Organization", "name": "Institute of Tandem Repeats, Noboribetsu 059-0464, Japan." } }, { "@type": "Person", "name": "Jean-Louis Mergny", "url": "https://questionsmedicales.fr/author/Jean-Louis%20Mergny", "affiliation": { "@type": "Organization", "name": "Laboratoire d'Optique et Biosciences, Ecole Polytechnique, CNRS, Inserm, Institut Polytechnique de Paris, 91128 Palaiseau, France." } }, { "@type": "Person", "name": "Yan Yan", "url": "https://questionsmedicales.fr/author/Yan%20Yan", "affiliation": { "@type": "Organization", "name": "Department of Emergency Medicine, Affiliated Hospital of Nantong University, Nantong, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Differentiating Enchondromas and Atypical Cartilaginous Tumors in Long Bones with Computed Tomography and Magnetic Resonance Imaging.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36140587", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/diagnostics12092186" } }, { "@type": "ScholarlyArticle", "name": "Environment-friendly transesterification to seawater-degradable polymers expanded: Computational construction guide to breaking points.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36088968", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.chemosphere.2022.136381" } }, { "@type": "ScholarlyArticle", "name": "Computational Insights into the Sequence-Activity Relationships of the NGF(1-14) Peptide by Molecular Dynamics Simulations.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36139382", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cells11182808" } }, { "@type": "ScholarlyArticle", "name": "Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening.", "datePublished": "2022-09-07", "url": "https://questionsmedicales.fr/article/36087860", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jtho.2022.08.011" } }, { "@type": "ScholarlyArticle", "name": "Financial incentives facilitate stronger neural computation of prosocial decisions in lower empathic adult females.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36064327", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/17470919.2022.2115550" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Séquence riche en AT", "item": "https://questionsmedicales.fr/mesh/D020856" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Séquence riche en AT - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Séquence riche en AT", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Séquence riche en AT", "description": "Comment identifier une séquence riche en AT ?\nQuels tests génétiques sont utilisés ?\nLes séquences riches en AT sont-elles visibles en microscopie ?\nPeut-on détecter des mutations dans ces séquences ?\nQuel rôle jouent les séquences riches en AT dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D020856?mesh_terms=Computer+Graphics&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Séquence riche en AT", "description": "Quels symptômes sont associés aux anomalies des séquences riches en AT ?\nLes séquences riches en AT causent-elles des maladies ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes séquences riches en AT affectent-elles le système immunitaire ?\nPeut-on prédire des symptômes par l'analyse des séquences ?", "url": "https://questionsmedicales.fr/mesh/D020856?mesh_terms=Computer+Graphics&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Séquence riche en AT", "description": "Peut-on prévenir les anomalies des séquences riches en AT ?\nQuels conseils pour les familles à risque ?\nL'éducation génétique est-elle importante ?\nLes tests prénataux peuvent-ils aider ?\nY a-t-il des recommandations diététiques ?", "url": "https://questionsmedicales.fr/mesh/D020856?mesh_terms=Computer+Graphics&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Séquence riche en AT", "description": "Quels traitements ciblent les séquences riches en AT ?\nLes médicaments peuvent-ils cibler ces séquences ?\nY a-t-il des approches expérimentales en cours ?\nComment les traitements personnalisés sont-ils appliqués ?\nLes traitements peuvent-ils prévenir des complications ?", "url": "https://questionsmedicales.fr/mesh/D020856?mesh_terms=Computer+Graphics&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Séquence riche en AT", "description": "Quelles complications peuvent survenir ?\nLes complications sont-elles héréditaires ?\nComment gérer les complications ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?", "url": "https://questionsmedicales.fr/mesh/D020856?mesh_terms=Computer+Graphics&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Séquence riche en AT", "description": "Quels sont les facteurs de risque associés ?\nL'âge parental influence-t-il les risques ?\nLes facteurs environnementaux jouent-ils un rôle ?\nY a-t-il des tests pour évaluer les risques ?\nLes habitudes de vie affectent-elles les risques ?", "url": "https://questionsmedicales.fr/mesh/D020856?mesh_terms=Computer+Graphics&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier une séquence riche en AT ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'analyse bioinformatique des séquences d'ADN permet d'identifier les régions riches en AT." } }, { "@type": "Question", "name": "Quels tests génétiques sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de séquençage et des analyses PCR ciblées peuvent être utilisés." } }, { "@type": "Question", "name": "Les séquences riches en AT sont-elles visibles en microscopie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles ne sont pas visibles directement en microscopie, mais leur effet peut l'être." } }, { "@type": "Question", "name": "Peut-on détecter des mutations dans ces séquences ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations peuvent être détectées par séquençage ciblé des régions riches en AT." } }, { "@type": "Question", "name": "Quel rôle jouent les séquences riches en AT dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent influencer l'expression génique et être liées à certaines pathologies." } }, { "@type": "Question", "name": "Quels symptômes sont associés aux anomalies des séquences riches en AT ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les anomalies peuvent entraîner des troubles génétiques, mais les symptômes varient." } }, { "@type": "Question", "name": "Les séquences riches en AT causent-elles des maladies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être associées à des maladies génétiques, mais ne causent pas directement." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes dépendent de la maladie associée, comme des anomalies de développement." } }, { "@type": "Question", "name": "Les séquences riches en AT affectent-elles le système immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent influencer l'expression de gènes immunitaires, mais pas directement." } }, { "@type": "Question", "name": "Peut-on prédire des symptômes par l'analyse des séquences ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'analyse peut aider à prédire des risques, mais pas tous les symptômes." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des séquences riches en AT ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un suivi génétique peut aider à identifier les risques." } }, { "@type": "Question", "name": "Quels conseils pour les familles à risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Consulter un conseiller en génétique pour évaluer les risques et options de dépistage." } }, { "@type": "Question", "name": "L'éducation génétique est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle aide à comprendre les risques et les implications des séquences riches en AT." } }, { "@type": "Question", "name": "Les tests prénataux peuvent-ils aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests prénataux peuvent détecter certaines anomalies génétiques liées aux séquences." } }, { "@type": "Question", "name": "Y a-t-il des recommandations diététiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la santé génétique, mais n'influence pas directement." } }, { "@type": "Question", "name": "Quels traitements ciblent les séquences riches en AT ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitements spécifiques, mais des thérapies géniques peuvent être envisagées." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils cibler ces séquences ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent influencer l'expression des gènes associés, indirectement." } }, { "@type": "Question", "name": "Y a-t-il des approches expérimentales en cours ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des recherches sur les thérapies géniques et les modulateurs d'expression sont en cours." } }, { "@type": "Question", "name": "Comment les traitements personnalisés sont-ils appliqués ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sont adaptés en fonction des mutations spécifiques dans les séquences." } }, { "@type": "Question", "name": "Les traitements peuvent-ils prévenir des complications ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un traitement précoce peut réduire le risque de complications associées." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications génétiques, des troubles de développement et des maladies associées." } }, { "@type": "Question", "name": "Les complications sont-elles héréditaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être héréditaires, selon la mutation spécifique." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une approche multidisciplinaire est souvent nécessaire pour gérer les complications." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent avoir un impact significatif sur la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des risques de complications à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines anomalies peuvent entraîner des complications à long terme, nécessitant un suivi." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque associés ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, l'exposition environnementale et certaines mutations génétiques." } }, { "@type": "Question", "name": "L'âge parental influence-t-il les risques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge avancé des parents peut augmenter le risque de certaines anomalies génétiques." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines ou radiations peut influencer les risques génétiques." } }, { "@type": "Question", "name": "Y a-t-il des tests pour évaluer les risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent évaluer les risques associés aux séquences riches en AT." } }, { "@type": "Question", "name": "Les habitudes de vie affectent-elles les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de vie saines peuvent réduire certains risques génétiques." } } ] } ] }

Sources (10000 au total)

Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening.

Despite evidence from clinical trials of favorable shifts in cancer stage and improvements in lung cancer-specific mortality, the effectiveness of lung cancer screening (LCS) in clinical practice has ... We performed a multicenter cohort study of patients diagnosed with a primary lung cancer between January 1, 2014, and September 30, 2019, at one of four U.S. health care systems. The primary outcome v... A total of 3678 individuals were diagnosed with an incident lung cancer during the study period; 404 (11%) of these patients were diagnosed after initiation of LCS. As screening volume increased, the ... Implementation of LCS at four diverse health care systems has resulted in a favorable shift to a higher incidence of stage I cancer with an associated decline in stage IV disease. Overall lung cancer ...

Clinical predictors of pulmonary embolism for inpatients: are computed tomography pulmonary angiograms being requested appropriately?

The heterogeneity of inpatient pulmonary embolism (PE) presentations may lead to computed tomography pulmonary angiograms (CTPA) being over-requested. Current clinical predictors for PE, including Wel... To determine the clinical indicators for ordering inpatient CTPA and the predictors of positive scans for PE.... Consecutive inpatient CTPA (performed >24 h after admission) from January 2017 to December 2017 were retrospectively reviewed. Variables including baseline characteristics, vital signs and risk factor... A total of 312 CTPA was reviewed (average patient age 67 years; 46% male) and 36 CTPA were positive for PE (11.5%). The average time to inpatient CTPA request was 7 days. Clinical indicators associate... Inpatient CTPA appear to be over-requested and can potentially be rationalised based on a combination of clinical predictors and Wells criteria and/or PERC rule. Further prospective studies are needed...

Maxillary sinus volume in patients with canted occlusal plane: A cone-beam computed tomography study.

To compare the maxillary sinus volume between both sides in adult patients with upper occlusal canting (>2 mm cant) and a control group (≤2 mm cant) using cone-beam computed tomography scans.... This retrospective study included a total of 84 scans (42 scans per group) according to predetermined selection criteria. OnDemand 3-D™ software was used for volumetric and linear measurements of the ... The median difference in the maxillary sinus volume between the sides was statistically significant between the control and cant groups (P < 0.001). Also, the median difference in the maxillary sinus ... In adult patients, maxillary occlusal canting of more than 2 mm was associated with asymmetric maxillary sinus volumes. In the cant group, maxillary first molars on the canted-down side were in close ...

Morphological changes in nerve rootlets in patients with cervical radiculopathy assessed using computed tomography myelogram.

There are only a few reports that utilize computed tomography myelogram (CTM) to define cervical nerve rootlet compromise in patients with radiculopathy. Here, we assessed the characteristic morpholog... CTMs were analyzed to elucidate morphological changes in nerve rootlets in 31 patients/32 cases with cervical radiculopathy. Notably, three of the four neurosurgeons evaluating these CTM had to agree ... Our findings included; posterior deviation of the ventral rootlet on the sagittal section (63%), ventral rootlet meandering or horizontalization (52%), and dorsal rootlet meandering (39%) on the coron... CTM better defines the anatomy, pathology, and radiology impacting the anterior or posterior cervical roots in patients presenting with cervical radiculopathy....